FDA Approves Foundation Medicine Liquid Biopsy Test As Companion Diagnostic For Lynparza
Executive Summary
The US FDA expanded the use of FoundationOne Liquid CDx as a companion diagnostic for certain prostate cancer patients eligible for treatment with olaparib.
You may also be interested in...
AstraZeneca Partners With AmoyDx On Companion Diagnostics For Lynparza
Teaming again with the Shanghai biotech, AstraZeneca will seek assays that can be incorporated into companion diagnostics for Lynparza in prostate and breast cancer.
AstraZeneca Partners With AmoyDx On Companion Diagnostics For Lynparza
Deal Snapshot: Teaming again with the Shanghai biotech, AstraZeneca will seek assays that can be incorporated into companion diagnostics for Lynparza in prostate and breast cancer.
Partnerships Are Key To Foundation Medicine's Success
Since receiving approval for the first broad-panel diagnostic test as a combination product to detect cancer, Foundation Medicine has ramped up its partnerships with pharmaceutical companies and other stakeholders. The company expects to receive a similar approval for a broad-panel liquid biopsy genomic test in the first half of 2020.